CSIMarket
 


Flexion Therapeutics Inc   (FLXN)
Other Ticker:  
 
 

FLXN's Capital Expenditures Growth by Quarter and Year

Flexion Therapeutics Inc 's Capital Expenditures results by quarter and year




FLXN Capital Expenditures (in millions $) FY 2021 FY 2020 FY 2019 FY 2018
IV Quarter December - 1.21 2.78 0.16
III Quarter September 0.47 3.32 0.05 0.13
II Quarter June 0.46 2.29 0.00 0.23
I Quarter March 0.80 3.24 1.07 0.33
FY   1.73 10.06 3.90 0.85



FLXN Capital Expenditures third quarter 2021 Y/Y Growth Comment
Flexion Therapeutics Inc reported drop in Capital Expenditures in the third quarter 2021 by -85.78% to $ 0.47 millions, from the same quarter in 2020.
The fall in the third quarter 2021 Flexion Therapeutics Inc 's Capital Expenditures compares unfavorably to the Company's average Capital Expenditures fall of -14.36%.

Looking into third quarter 2021 results within Major Pharmaceutical Preparations industry 164 other companies have achieved higher Capital Expenditures growth. While Flexion Therapeutics Inc ' s Capital Expenditures meltdown of -85.78% ranks overall at the positon no. 2912 in the third quarter 2021.




FLXN Capital Expenditures ( Y/Y Growth %) 2021
2020 2019 2018
IV Quarter December - -56.47 % 1637.5 % -38.46 %
III Quarter September -85.78 % 6540 % -61.54 % -35 %
II Quarter June -79.91 % - - -65.15 %
I Quarter March -75.31 % 202.8 % 224.24 % -67.65 %
FY   - 157.95 % 358.82 % -60.28 %

Financial Statements
Flexion Therapeutics Inc 's third quarter 2021 Capital Expenditures $ 0.47 millions FLXN's Income Statement
Flexion Therapeutics Inc 's third quarter 2020 Capital Expenditures $ 3.32 millions Quarterly FLXN's Income Statement
New: More FLXN's historic Capital Expenditures Growth >>


FLXN Capital Expenditures (Quarter on Quarter Growth %)

2021
2020 2019 2018
IV Quarter December - -63.55 % 5460 % 23.08 %
III Quarter September 2.61 % 44.98 % - -43.48 %
II Quarter June -42.5 % -29.32 % - -30.3 %
I Quarter March -33.88 % 16.55 % 568.75 % 26.92 %
FY (Year on Year)   - 157.95 % 358.82 % -60.28 %




Capital Expenditures third quarter 2021 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #165
Healthcare Sector #519
Overall #2912

Capital Expenditures Y/Y Growth Statistics
High Average Low
39.12 % -14.36 % -49.17 %
(Sep 30 2020)   (Sep 30 2021)
Capital Expenditures third quarter 2021 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #165
Healthcare Sector #519
Overall #2912
Capital Expenditures Y/Y Growth Statistics
High Average Low
39.12 % -14.36 % -49.17 %
(Sep 30 2020)   (Sep 30 2021)

Capital Expenditures by Quarter for the Fiscal Years 2018, 2019, 2020, 2021

Flexion Therapeutics Inc 's Q/Q Capital Expenditures Growth


Capital Expenditures Q/Q Growth Statistics
High Average Low
5452 % 264.6 % -100 %
(Dec 31 2019)  


FLXN's III. Quarter Q/Q Capital Expenditures Comment
Flexion Therapeutics Inc achieved in the III. Quarter 2021 below company average Capital Expenditures growth of 2.61% quarter on quarter, to $ 0.47 millions.

Within Major Pharmaceutical Preparations industry 129 other companies have achieved higher Capital Expenditures quarter on quarter growth. While Flexion Therapeutics Inc 's Capital Expenditures growth quarter on quarter, overall rank is 1803.


Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #130
Healthcare Sector #353
Overall #1803
Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #130
Healthcare Sector #353
Overall #1803
Capital Expenditures Q/Q Growth Statistics
High Average Low
5452 % 264.6 % -100 %
(Dec 31 2019)  


FLXN's III. Quarter Q/Q Capital Expenditures Comment
Flexion Therapeutics Inc achieved in the III. Quarter 2021 below company average Capital Expenditures growth of 2.61% quarter on quarter, to $ 0.47 millions.

Within Major Pharmaceutical Preparations industry 129 other companies have achieved higher Capital Expenditures quarter on quarter growth. While Flexion Therapeutics Inc 's Capital Expenditures growth quarter on quarter, overall rank is 1803.


Flexion Therapeutics Inc 's 12 Months Capital Expenditures Growth Year on Year


Capital Expenditures TTM Growth

12 Months Ending
(Sep 30 2021)
12 Months Ending
(Jun 30 2021)
12 Months Ending
(Mar 31 2021)
12 Months Ending
(Dec 31 2020)
12 Months Ending
(Sep 30 2020)
Cumulative Capital Expenditures 12 Months Ending $ 2.95 $ 5.80 $ 7.63 $ 10.07 $ 11.64
Y / Y Capital Expenditures Growth (TTM) -74.68 % -30.7 % - - -
Year on Year Capital Expenditures Growth Overall Ranking # 2225 # 1733 # 0 # 0 # 0
Seqeuential Capital Expenditures Change (TTM) -49.17 % -24 % -24.26 % -13.47 % 39.12 %
Seq. Capital Expenditures Growth (TTM) Overall Ranking # 816 # 2468 # 2579 # 1790 # 820




Cumulative Capital Expenditures growth Comment
Flexion Therapeutics Inc 's cumulative 12 months Capital Expenditures continue to drop, but on the faster rate at -74.68% year on year, at Sep 30 2021 compare to the -30.7% decrease at Jun 30 2021. If the Flexion Therapeutics Inc 's fiscal year would end at Sep 30 2021, annual Capital Expenditures would be $3 millions.

In the Healthcare sector 356 other companies have achieved higher trailing twelve month Capital Expenditures growth. While Capital Expenditures growth total ranking has deteriorated compare to previous quarter from 1733 to 2225.

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
278.62 %
-16.53 %
-80.3 %
 

Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 74
Healthcare Sector # 357
Overall # 2225

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
278.62 %
-16.53 %
-80.3 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry # 74
Sector # 190
S&P 500 # 816
Cumulative Capital Expenditures growth Comment
Flexion Therapeutics Inc 's cumulative 12 months Capital Expenditures continue to drop, but on the faster rate at -74.68% year on year, at Sep 30 2021 compare to the -30.7% decrease at Jun 30 2021. If the Flexion Therapeutics Inc 's fiscal year would end at Sep 30 2021, annual Capital Expenditures would be $3 millions.

In the Healthcare sector 356 other companies have achieved higher trailing twelve month Capital Expenditures growth. While Capital Expenditures growth total ranking has deteriorated compare to previous quarter from 1733 to 2225.

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
278.62 %
-16.53 %
-80.3 %
 


Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 74
Healthcare Sector # 357
Overall # 2225

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
278.62 %
-16.53 %
-80.3 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry # 74
Sector # 190
S&P 500 # 816




Other Capital Expenditures Growth
Major Pharmaceutical Preparations Industry Capital Expenditures Growth Trends and Statistics
Healthcare Sector Capital Expenditures Growth Statistics
Capital Expenditures Growth Trends for overall market
FLXN's Capital Expenditures Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Capital Expenditures Growth
Lowest Ranking Capital Expenditures Growth
Capital Expenditures Growth for FLXN's Competitors
Capital Expenditures Growth for Flexion Therapeutics Inc 's Suppliers
Capital Expenditures Growth for FLXN's Customers

You may also want to know
FLXN's Annual Growth Rates FLXN's Profitability Ratios FLXN's Asset Turnover Ratio FLXN's Dividend Growth
FLXN's Roe FLXN's Valuation Ratios FLXN's Financial Strength Ratios FLXN's Dividend Payout Ratio
FLXN's Roa FLXN's Inventory Turnover Ratio FLXN's Growth Rates FLXN's Dividend Comparisons



Companies with similar Capital Expenditures drop for the quarter ending Sep 30 2021 within Healthcare SectorY/Y Change %Capital Expenditures for the quarter ending Sep 30 2021
Davita Inc -0.01%$ -0.008 millions
National Research Corporation-1.59%$ -1.587 millions
Owens and Minor inc-2.06%$ -2.065 millions
Quest Diagnostics Inc-2.20%$ -2.198 millions
Community Health Systems Inc -2.40%$ -2.400 millions
Alimera Sciences Inc -2.52%$ -2.516 millions
Ptc Therapeutics inc -2.61%$ -2.611 millions
Adma Biologics Inc -3.34%$ -3.342 millions
Neubase Therapeutics inc -3.47%$ -3.467 millions
Arvinas Inc -4.18%$ -4.176 millions
Universal Health Services Inc -4.29%$ -4.286 millions
Global Blood Therapeutics Inc.-4.41%$ -4.412 millions
Inspire Medical Systems inc -5.27%$ -5.267 millions
Avidity Biosciences Inc -5.33%$ -5.325 millions
3m Company-6.79%$ -6.793 millions
Abbott Laboratories-7.06%$ -7.056 millions
Bruker Corporation-7.39%$ -7.386 millions
Retractable Technologies inc -8.17%$ -8.166 millions
Calcimedica Inc -8.63%$ -8.629 millions
Cerus Corporation-8.68%$ -8.678 millions
Mallinckrodt Plc-9.91%$ -9.910 millions
Tivity Health Inc -9.92%$ -9.921 millions
Syneos Health Inc -9.92%$ -9.923 millions
Invacare Holdings Corporation-10.01%$ -10.008 millions
Gilead Sciences Inc -10.32%$ -10.323 millions
Tg Therapeutics Inc -11.24%$ -11.236 millions
Orthofix Medical Inc -11.36%$ -11.358 millions
Si bone inc -11.88%$ -11.875 millions
Orasure Technologies Inc-11.89%$ -11.891 millions
Agile Therapeutics Inc-12.16%$ -12.162 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com